University of Memphis

University of Memphis Digital Commons
Electronic Theses and Dissertations
5-3-2018

Development and Functional Evaluation of Chitosan Paste as a
Local Antibiotic Delivery Biomaterial
Christopher Michael Alexander

Follow this and additional works at: https://digitalcommons.memphis.edu/etd

Recommended Citation
Alexander, Christopher Michael, "Development and Functional Evaluation of Chitosan Paste as a Local
Antibiotic Delivery Biomaterial" (2018). Electronic Theses and Dissertations. 1810.
https://digitalcommons.memphis.edu/etd/1810

This Thesis is brought to you for free and open access by University of Memphis Digital Commons. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of University of
Memphis Digital Commons. For more information, please contact khggerty@memphis.edu.

DEVELOPMENT AND FUNCTIONAL EVALUATION OF CHITOSAN PASTE
AS A LOCAL ANTIBIOTIC DELIVERY BIOMATERIAL

By
Christopher Michael Alexander

A Thesis
Submitted in Partial Fulfillment Of the
Requirements for the Degree of
Master of Science

Major: Biomedical Engineering

The University of Memphis
May 2018

Copyright© 2018 Christopher Michael Alexander
All rights reserved

ii

PREFACE
The main body of this thesis in Chapter 3 is a journal article entitled
“Development and Evaluation of Chitosan Paste as a Local Antibiotic Delivery System
for Trauma Care”, which will be submitted to the International Journal of Biological
Macromolecules.
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ABSTRACT
Complex musculoskeletal wounds, resultant of high-energy trauma, are a leading
cause of morbidity worldwide due, in part, to a propensity for bacterial contamination.
This work details the fabrication of a thermo-responsive, injectable chitosan composite
paste by including the additive β-glycerophosphate, which creates a polyelectrolyte
complex with the chitosan molecular backbone. Functional and clinical efficacy as an
infection prevention tool were determined within the scope of complex musculoskeletal
wounds. Findings from in vitro studies support the capability of chitosan paste to be
loaded with dual antibiotics for release of inhibitory levels of both amikacin and
vancomycin for at least 3 days. Further, rates of enzymatic degradation of approximately
60% of the initial mass were observed within 7 days. The cytocompatibility of the
thermogel requires enhancement; eliciting the lowest cell count among all experimental
groups, approximately 77% of the Control Chitosan Sponge group. The thermogel
ejection force, approximately 20N, is significantly lower than comparable, previously
studied chitosan paste formulations. A preclinical, compatibility study of thermogel
exposed to both hard and soft tissues demonstrated the paste to be capable of
implantation for up to 7 days, inducing inflammatory responses similar to previously
studied chitosan pastes. No significant differences were found in the rate of clearance in
a murine, polymicrobial defect, though average CFUs retrieved from explants were lower
compared to control groups. Results indicate the thermogel is a compatible, degradable
biomaterial capable of therapeutic, local antibiotic release for up to 7 days.
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CHAPTER 1
INTRODUCTION
Statement of Problem
High-energy trauma to the musculoskeletal system can cause a complex wound
characterized by lacerations and abrasions, open fractures, hematoma formation, and
tissue necrosis [2-6]. The World Health Organization estimates traumatic injuries to
the musculoskeletal system are the fourth leading cause of morbidity worldwide,
responsible for five million annual fatalities [7, 8]. Unfortunately, the incidence of
traumatic musculoskeletal injuries and accompanying morbidity is growing as the
unsafe use of motorized vehicles increases in third-world and developing countries.
Consequently, 95% of deaths related to traumatic injuries occur within low or middleincome countries [7]. Reports have estimated if trauma care in under-developed
socioeconomic countries was as established in “high income” countries, then two
million lives could potentially be saved each year. Even, a more conservative
estimate states an 8% improvement in injury mortality rates in low and middle
income countries would result in 400,000 lives saved annually [9].
A primary contributor to morbidity and mortality associated with complex
musculoskeletal wounds is the high risk of bacterial contamination, with infection
rates ranging from 20% of civilian injuries [10-12] to 65% of orthopaedic trauma
suffered [11, 13]. Necrotic tissue surrounding the wound experiences a diminished
perfusion of bodily fluids, effectively restricting leukocytes and IV antibiotics from
accessing the wound via vascular pathways [6]. Furthermore, the complex

morphology of a severe musculoskeletal wound can contribute to increased surface area
that could allow for the adherence of invading planktonic bacteria, the initiating
mechanism in the formation of biofilm [14, 15]. Biofilm is defined as bacteria
attached to a surface, characterized by a self-produced matrix of exopolysaccharides,
DNA, and proteins. The senescent nature of biofilm bacteria in addition to the
exopolymeric matrix contributes to antibiotic resistance, with minimum inhibitory
concentrations (MIC) up to 1000 times greater than the planktonic form [14-16].
Biofilm-forming bacterial strains (i.e. Staphylococcus aureus, Pseudomonas aeruginosa)
are among the most commonly identified species in complex musculoskeletal infections
[17, 18]. Some biofilm-based infections can be eradicated with antibiotics administered
systemically, but at dangerously high concentrations. Antibiotics, especially
glycopeptides such as vancomycin, can cause harm to the patient at high concentrations
including nephrotoxicity and ototoxicity, among other ailments [19].
Local antibiotic delivery systems have been designed to release inhibitory levels of
antibiotic within the wound long enough to treat the infection while maintaining safe
systemic concentrations [20-22]. Local antibiotic delivery devices can be applied as an
adjunct treatment to the standard prophylactic method of IV delivery [20, 23]. Common
biomaterials for local delivery systems include poly(methyl-methacrylate), calcium
sulfate, and poly(glycolic-acid), among many others [23, 25, 30]. However, there are
shortcomings that limit the efficacy of these materials as local antibiotics delivery
vehicles, including degradation rates and potential toxicity of degradation products [24,
19, 28].
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The current report focuses on chitosan, a naturally derived, linear polysaccharide
comprised of randomly dispersed glucosamine and N-acetyl glucosamine monomer units
linked by glycosidic bonds in a β(1-4) pattern [24]. With a unique polycationic
backbone, favorable compatibility, and bio-resorbable nature; chitosan has a wide
range of medical applications. Additionally, many material characteristics such as
degradation or drug release can be tailored via modification of the crystallinity,
molecular weight, degree of deacetylation of chitosan, as well as chemical or physical
crosslinking of synthetic additives [25-27]. Recent studies have demonstrated the
feasibility of chitosan as a constituent of effective local antibiotic delivery systems in
as the form of lyophilized chitosan sponges [28-33]. However, chitosan sponges may
have limited efficacy preventing infection in complex musculoskeletal wounds due to
an inability to conform to the complex morphology, as well as an initial burst release
of the loaded antibiotics [34, 35].
To address the limitations of chitosan in a sponge form, an injectable paste
variation of finely ground, lyophilized chitosan hydrated with antibiotic loaded saline
has shown to have potential as an effective infection-prevention tool within
musculoskeletal wound trauma care [1, 36]. The present report will detail the
fabrication of the experimental thermogel chitosan paste, formed by compositing with
β-glycerophosphate (β-GP). The resulting product is a thermo-responsive paste that
undergoes a temperature-dependent gelation process as the paste approaches body
temperature. Following the fabrication, the investigation into the functional and
clinical efficacy of thermogel is conducted via in vitro models of cytocompatibility,
antibiotic release characteristics, enzymatic degradation, and injectability. The
3

clinical potential of the paste is evaluated via preclinical studies of functional
compatibility and antimicrobial efficacy.
Hypothesis and Research Objectives
It is hypothesized the thermogel chitosan paste formulation, containing βglycerophosphate (β-GP), will form a biocompatible, bio-resorbable, temperatureresponsive drug delivery polymer. The thermogel will be capable of point-of-care
antibiotic loading via hydration; exhibit favorable injectability at room temperature
(20ºC) and subsequent in situ gelation as the environmental temperature rises to bodily
levels (37ºC); and local, therapeutic release in vivo for at least 72 hrs. The goal of the
work reported in the current study is to develop a partially injectable infection-prevention
tool to be used in trauma care, effectively reducing the incidence of morbidity associated
with musculoskeletal wounds resultant of traumatic injuries.
The research objectives can be broken into the functional and preclinical evaluations
of the thermogel as a local antibiotic delivery device relevant in trauma care, assessed
with respect to previously researched chitosan-based local drug delivery systems. The
functionality of the paste was evaluated via investigations into the paste cytotoxicity to
murine fibroblast-like cells, in vitro antibiotic release profiles of the experimental
samples dual-loaded with vancomycin and amikacin, and the rate of in vitro enzymatic
degradation. Material properties of the paste were investigated via studies of ease of
ejection from a syringe, bio-adhesive characteristics, ability of the paste to conform to a
representative wound bed, as well as a model of the antibiotic diffusivity from the paste
into a narrow, deep, complex wound. Preclinical efficacy of the paste is evaluated via two
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models: a functional biocompatibility model, and an antimicrobial efficacy model in a
functional infected orthopaedic study.
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CHAPTER 2
LITERATURE REVIEW
Musculoskeletal Injury
Damage inflicted to the soft, hard, and connective tissue of the musculoskeletal system
can result in a superficial wound such as an abrasion, avulsion, or laceration; and can
cause internal damage such as a fractured bone or torn connective tissue [37]. Globally,
traumatic injuries are the leading cause of morbidity in individuals under 45, and the
fourth leading cause among all age groups [8]. A 2007 investigation conducted by the
World Health Organization into the rates of hospital admission for non-fatal traumatic
injuries worldwide revealed the majority of all reported injuries involved the
musculoskeletal system; “open wound” being the most frequently occurring resultant
injury of the reported trauma [38]. The rate of traumatic injury as well as the mortality
rate of these injuries are nearly double in low and middle-income countries compared to
high-income countries such as the United States [39]. Additionally, the mortality rate is
steadily rising due in part to increased use of motorized transport and the lack of proper
trauma care systems throughout the majority of the world [40]. It has been estimated
there are over five million traumatic injury-related deaths annually, with 95% of these
deaths occurring within the low or middle income countries [7]. A report by Rivara et al.
emphasized the socioeconomic differences in traumatic injury mortality rate by
estimating that two million lives could potentially be saved each year if improvements in
injury mortality rates in low and middle income countries reach the levels in developed
countries [9]. Trauma care is a global healthcare concern and efficient, sustainable
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strategies to provide orthopaedic trauma care is an important step in mitigating the
impact of traumatic injuries [41].
The Wound Healing Process and Risks Associated with Musculoskeletal Trauma
Injuries involving both blunt and penetrating trauma can damage the tissue of the
musculoskeletal system in a non-uniform pattern and form an irregular wound bed
topography. Wounds of this nature are identified as complex, a term to describe
wounds spanning multiple tissue types, often the result of devastating injuries, and
requiring an extended healing time [2, 6, 42].
Following coagulation, the early inflammation phase begins with the activation of
the complement components which work to repair the wound beginning with the
recruitment of phagocytic neutrophils to the site to destroy and remove foreign
contaminants such as bacteria via the release of proteolytic enzymes and oxygenderived free radicals [3, 43]. The late inflammatory phase is characterized by the
arrival of macrophages which work with neutrophils to debride the wound site,
combat invading microorganisms, and provide essential tissue growth factors [44].
At approximately 72h post injury, the inflammatory stage transitions to the
proliferative phase, a multi-week process of tissue regeneration during which
fibroblast cells migrate into the provisional matrix of fibrin and platelets and form
new extracellular matrix referred to as granulation tissue. The newly formed tissue
consists of fibroblasts, macrophages, and vasculature-forming endothelial cells within
a matrix of fibronectin, collage, and hyaluronic acid. In complex traumatic wounds,
these processes may be impaired or delayed due to vascular injury. Impairment of
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neutrophils or macrophages could lead to reduced phagocytosis of bacterial
contaminants, which could in turn lead to infection and impaired healing[44-46].
The jagged, irregular bed of a complex wound bed provides a sheltered region of high
surface area that is very favorable for the proliferation of bacteria and biofilm formation.
Penetrating trauma can incorporate contaminants such as clothing or sediment into the
wound, increasing contamination and the risk of subsequent infection [2]. Adherence of
planktonic bacteria to a surface leads to biofilm formation. Low metabolic activity of
biofilm bacteria protects the encased bacteria from antimicrobial agents and immune cell
attack [15, 16]. A study by Costerton et al. [14] of Pseudomonas aeruginosa revealed a
1000-fold increase in the minimal inhibitory concentration of bacteria growing in
biofilms compared to the planktonic counterparts. Stable biofilms can develop into
densely populated networks of microorganisms which can detach and seed further sites of
infection and can cause tissue destruction and systemic infection [15, 47] The presence of
inflammatory agents induced by the biofilm causes an increased mutation rate of the
microbes, which can contribute to the adaptation of the biofilm microbes by induction of
antibiotic resistance and increased resilience [48]. The most common biofilm-producing
organisms found in orthopedic infections are Staphylococcus aureus (Fig. 1), coagulasenegative staphylococci, beta-hemolytic streptococci, and aerobic gram-negative rods,
such as Pseudomonas aeruginosa [17, 18].
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Figure 1: SEM photo of S. aureus exhibiting biofilm formation on an orthopaedic implant
extracted from an infected murine model.
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Complex musculoskeletal wounds suffered by civilians, often resulting from
automobile accidents, have an estimated 20% chance of infection [10-12]. However,
complex orthopaedic trauma suffered by soldiers in a combat situation exhibit an
estimated 65% rate of infection [11, 13]. A large-scale bacteriological study by CarsentiEtesse et al. of 1000 patients being treated for open leg fractures provides evidence of
bacterial contamination in traumatic wounds. Cultures were obtained from open fracture
wounds at the time of admission and again at various stages throughout the treatment
process, categorized by the antibiotic used for treatment. The wound contamination rate
at the time of admission ranged from 26-30%, reaffirming the susceptibility of traumatic
wounds to infection. After 3 months of treatments the infection rate of patients ranged
from 6.6-8%. Additionally, there was a higher rate of antibiotic resistance in bacterial
strains that had been cultured after systemic antibiotic treatment [49]. The results of open
fracture epidemiology detailed by Carsenti-Etesse et al. demonstrate the high rate of
initial contamination in open musculoskeletal wounds, the incidence of chronic infection
regardless of systemic delivery, and the correlation between an increased rate of bacterial
antibiotic resistance after IV antibiotic administration. Results of the Carsenti-Etesse et
al. study are in agreement with the findings of a 1974 clinical study by Patzakis et al. on
the role of antibiotics in open fracture management. For 10 days, the infection rate was
investigated in the treatment of 333 open fractures treated with IV administration of
cephalothin, a penicillin and streptomycin combination, or no antibiotic treatment at all.
There was no statistically significant difference between the infection rates of the group
receiving no antibiotics (13.9%) and the group receiving penicillin and streptomycin
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(9.7%), while the group receiving cephalothin (2.3%) was significantly lower than
those for the other two groups.
The surgical closure of an infected traumatic wound may be delayed in order to
allow the healing wound to gain resistance to infection and permit uncomplicated
closure. Johnson et al. demonstrated early closure in an infected wound causes the
formation of weaker granulation tissue than infected wounds with delayed closings
[50]. Patients with infected traumatic wounds typically undergo debridement of
necrotic tissue followed by wound dressings. The wound is left opened and
undisturbed for the first 4 days while antibiotic therapy is administered intravenously.
It is generally agreed upon that when the bacterial count of the tissue is lower than 105
organisms/gram of tissue, treatment can proceed with a delayed closure without a
major risk of infection [51]. There is a very small window of time between the injury
occurring and the proliferation of bacteria to a level capable of developing an
infection. In the world of emergency trauma care, a 6 h delay in treatment is
associated with a bacterial population estimate of 106 colony forming units of bacteria
per gram of tissue [52]. A wound exposed without treatment for 3h normally develops
a coagulum large enough to surround the bacteria in the wound and prevent contact
with either systemic or topical antibiotics. The exudate provides the opportunity for
contaminating microbes to develop a resistance to delayed antibiotic care. Therefore,
IV administration of antibiotics is standard prophylactic treatment for patients who are
believed to have contaminated wounds [5, 6].
Vasculature damage in the affected tissue causes that creates a favorable
environment for bacterial infection, since damaged vasculature limits access of
11

immune cells or intravenously administered antibiotics transported via cardiovascular
vessels. [10, 20]. Physiologically, antibiotics administered intravenous (IV) are
ineffective in hypoxic tissue, as there is no flowing conduit for antimicrobial diffusion
into the wound [53]. The bolus method of IV delivery creates a bioavailability profile of
a sinusoidal nature in which high systemic levels are reached upon injection followed by
a fast decline to ineffective levels until the next bolus delivery is administered. The
oscillating pattern of antibiotic levels could prove harmful to the wound healing process
by strengthening the bacterial infection in the wound [54]. Antibiotics present at levels
below the minimum inhibitory concentration in a bacterial infection can stimulate biofilm
production as a mechanism of antimicrobial resistance. Mlynek et al. investigated the
biofilm production of methicillin-resistant Staphylococcus aureus exposed to subinhibitory levels of amoxicillin compared to biofilm produced in the complete absence of
antibiotics [55]. At the low amoxicillin levels, bacteria show an increased tendency to
adhere to a surface and form a thick biofilm with a developed structured of channels and
pillar and less porous than antibiotic-free biofilm. Due to wound accessibility obstacles,
systemic administration of IV antibiotics is not an efficient method of therapeutic
delivery and an alternative method of delivery must be considered [23].
Local Antibiotic Delivery Systems
For musculoskeletal infections, local antibiotic delivery devices present the potential
for an alternative or adjunct treatment option to the standard prophylactic method of
systemic IV delivery. Due to a steep concentration gradient, antibiotics passively diffuse
from local areas of high antibiotic levels into avascular areas of wounds inaccessible by
systemic antibiotics. Biofilm-forming colonies of bacteria that would normally develop a
12

resistance to an antibiotic at lower levels experienced in systemic delivery, are
vulnerable at a high local concentration [56].
An ideally designed local antibiotic delivery system would provide an efficient
delivery of high levels of antibiotics to the site of infection while the systemic
concentration of antibiotics remained low to minimize the risks of systemic toxicity
associated with the traditional method of IV antibiotic delivery [20]. As a system that
will be implanted in the body for an extended amount of time, the biomaterial
properties of the local drug delivery vehicles must be closely assessed to minimize the
inflammation associated with foreign body response. Properties commonly evaluated
are cytotoxicity of the material, structural integrity of the scaffold, degradation of the
scaffold, and the elution rates of antibiotics from the scaffold. Antibiotic delivery
vehicles can be divided into nonbiodegradable and biodegradable classes, and the
degradable scaffolds can be categorized based on their properties and applications:
bone graft and graft substitutes, synthetic polymers, and natural polymers [22, 57].
Polymethylmethacrylate (PMMA) is a nonbiodegradable synthetic polymer used as
an artificial bone cement in orthopedic surgery, and can also function as a local
antibiotic delivery system [58-60]. Administered as beads, solid spacers, or
intramedullary nails, antibiotics delivered through PMMA biomaterials can be used to
treat large hard or soft tissue defects [61, 62]. However, the clinical use of PMMA as
a vehicle for local antibiotic therapy is not without its limitations. There is a limited
availability of antibiotics that are compatible with PMMA due to the physical and
chemical requirements of the mixing process. Water soluble antibiotics must be in
powder form, chemically stable, and effective against a broad bacterial spectrum in
13

order to be added to PMMA during the hydration and mixing stage. Since the exothermic
polymerization of the cement can raise temperatures up to 80ºC, antibiotics used in bone
cement systems must also be stable across a large range of temperatures [63].
Gentamicin, tobramycin, and vancomycin are commonly used with bone cement [64].
Since PMMA is a non-biodegradable local antibiotic delivery scaffold, the length of
implantation as well as the method of implant removal are major concerns. Prolonged
implantation may catalyze the development of antibiotic-resistant bacteria despite killing
bacteria during the elution phase. However, bacteria can still persist once the elution
phase has ended and the PMMA vehicle is perceived as a foreign body with antibiotics
being released below therapeutic levels. The foreign body creates a large surface for
bacterial adherence and subsequent biofilm production, a known potentiator of antibiotic
resistance in bacteria [65]. Many studies have investigated the negative effects of bone
cement, including a report by Wininger et al. which correlated the increase in the
prevalence of resistant bacteria with the introduction of antibiotic-loaded bone cement
[66]. The surgical removal of PMMA implants within 4 to 6 weeks after implantation is
recommended to avoid contamination and removal complications [67].

Degradability

concerns with PMMA have directed the research and development of delivery systems
towards an absorbable or biodegradable approach. Antibiotics have been incorporated
into bone autografts and allografts clinically for over 20 years [68]. Antibiotic powder
can be combined with morselized cancellous bone or by submersion of the graft in an
antibiotic solution [69]. A 1998 study by Chan et al. studied iliac cancellous bone grafts
impregnated with piperacillin and vancomycin via submersion in solution [70], finding
that infection clearance occurred at a rate of 94.4% and improved patient outcomes.
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Composite materials can be substituted for bone autografts, including calcium sulfate,
calcium phosphate, hydroxyapatite, and tricalcium phosphate. No form of degradable
local drug delivery system has been cleared by the Food and Drug Administration
(FDA) [20, 71]. However, bone substitute materials have been approved for use in the
repair of bony defects. As an infection prevention method, the treating physician may
mix the antibiotics into the bone graft substitute material when it is being mixed and
hydrated as in the PMMA delivery systems. Antibiotic-loaded calcium sulfate is the
most commonly used bone graft substitute material in hard tissue reconstruction of
osteomyelitis patients [72]. Its use as an antibiotic delivery system is in some cases
preferred over PMMA beads since there is no removal surgery needed [68, 73].
However, a faster degradation rate could be a cause for concern, leading to a rapid and
variable antibiotic elution profile and a high rate of resorption which presents
cytotoxicity issues [57]. Calcium sulfate has been shown to provoke an inflammatory
response resulting in increased fluid in the wound bed and opaque drainage which can
be perceived as the recurrence of infection [74]. The solid form of the material in bead
form may also limit its usage in complex musculoskeletal wounds, as the irregular
shape of the wound prevents the calcium sulfate beads or bone filler to properly
distribute the antibiotics.
The variability in elution and degradation properties of calcium sulfate has
motivated the investigation into synthetic polymers as local drug delivery vehicles.
Benefits of using synthetic polymers include the ability to predict and modify several
aspects of the local antibiotic delivery, as well as the opportunity to create a
composite-therapeutic delivery system of more than antibiotics, such as growth factors
15

to promote tissue regeneration or cytokines to attract specific cells or extracellular
proteins [57]. Poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and their respective
copolymers are the most common synthetic degradable polymers in medicine [75], and
can be advantageous as drug delivery systems due to the gradual degradation
demonstrated at physiological pH. The elution of the loaded antibiotic from some
synthetic polymers can be adjusted by varying the monomeric composition, crystallinity,
and molecular weight [21]. PLA and PGA implants elicit minimal inflammatory
responses which subside as the polymer is gradually absorbed [76]. Another benefit is
the wide range of antibiotics compatible with synthetic polymers for in vivo release for a
definite time period at an effective concentration [77].
Recently, research has focused on the development of a bioabsorbable gel as an
antibiotic delivery vehicle capable of releasing all carried antibiotics as it degrades and
provides a uniform distribution of antibiotics throughout the wound as opposed to
discrete pockets around PMMA or calcium sulfate beads. A 2014 report by PennBarwell et al. [22] details the 14 day treatment of an open femoral defect in a rat model
inoculated with S. aureus via application of a bioabsorbable phospholipid gel loaded with
both vancomycin and gentamicin or PMMA beads loaded with vancomycin or
tobramycin. The gel demonstrated complete wound coverage and a significantly lower
infection rate than the PMMA beads; authors concluded it to be a novel and effective
option for a local antibiotic delivery. Recent advances in additive manufacturing
technology have motivated the need for printable gels capable of structural support for
the production of tissue engineering scaffolds via layered deposition [78]. Limitations of
synthetic polymers include the loss of structural integrity as the polymer degrades
16

throughout treatment as well as the relatively low supply of synthetic polymers cleared
for use in the medical field [20].
Natural polymers are advantageous for local delivery in part for the ability to be
degraded due via in vivo enzymes and metabolic pathways, resulting in minimal
foreign body response from the host [79]. Yet clinical issues are still presented by
natural polymers such as immunogenicity, lot-to-lot variability, molecular complexity,
and inadequate mechanical properties [80]. . Naturally derived materials commonly
implemented within the biomedical field include alginate, collagen, fibrin, and
chitosan. Alginate is a material constituted of linear, anionic polysaccharides derived
from kelp or algae, and can be cross-linked by various agents to form a hydrogel, a
term referring to a hydrophilic polymer with a very high-water content. Since alginate
is foreign to mammalian cells, the polysaccharide chains making up the alginate
molecule cannot be naturally broken enzymatically in vivo, resulting in compromised
degradation control. Alginate hydrogels can be tailored to be used as drug delivery
vehicles, among many other applications, and have been approved by the FDA as a
topical wound dressing capable of providing a microbial barrier in some products [81].
The most widely researched natural biodegradable polymer is collagen. The structural
protein which accounts for over 90% of all fibrous proteins in animals is present in
virtually every type of tissue, resulting in an absorbable, biocompatible implant that
does elicits minimal foreign body response. Collagen can be chemically modified via
numerous documented cross-linking methods [82]. The chemical modifications alter
material properties which coincidentally can be manipulated to tailor the collagen to
specific therapeutic applications. Modifying a collagen sponge with increased
17

intermolecular crosslinks will decrease susceptibility to enzymatic degradation, decrease
solubility in aqueous solutions, and increase tensile strength, among many other effects.
Therefore, drug delivery characteristics such as antibiotic release and in vivo degradation
rate can be indirectly tailored [83, 84].

A 2013 study by Chang et al. investigated the

diagnoses of approximately 7000 orthopaedic surgery patients treated with gentamicinloaded collagen sponges to prevent bacterial contamination at the surgical site an did find
a decreased rates of surgical site infection [85].
It is important to note the compatibility benefits of natural polymers while also
considering the negatives such as batch variability and poor mechanical qualities.
Engineering composite blends of natural polymers is an approach to overcoming some of
the limitations of natural polymers, while preserving the natural cytocompatibility.

A

2014 report by Doty et al. [86] describes an extended in vitro release of vancomycin and
growth factors from a biodegradable composite bone graft constituted from calcium
sulfate embedded with chitosan microspheres.
An Introduction to Chitosan
Naturally occurring in the exoskeletons of crustaceans such as crab and shrimp, chitin
is the most abundant amino polysaccharide on earth. Capable of being sustainably
recycled from food processing plants, chitin is then subject to multiple refinement
processes, including an acid decalcification and an alkaline treatment to remove all
proteins [87]. The molecular structure of chitin is then de-acetylated in a reaction with a
strong alkali under high temperature and pressure. The resulting product is a variable
chain polymer characterized by a random distribution of glucosamine monomers
containing positively charged free amino groups (Fig. 2) [88, 89]. Chitosan and chitin are
18

terms referring to the same linear polysaccharide, compromised of a repeating chain of
glucosamine and N-acetyl glucosamine monomers linked in a β(1-4) glycosidic bond
pattern [24]. The degree of deacetylation (DDA) of a batch of chitosan describes the
ratio of glucosamine to N-acetyl glucosamine units in the polymer. A DDA of 50% or
greater constitutes the “chitosan” nomenclature and less than 50% is termed “chitin”
[90, 91]. Most commercially produced chitosan has a DDA ranging from 70 to 95%
and a relatively high molecular weight ranging from 300 to 1000 kDa, properties
which can affect the applications of chitosan [92]. Chitosan is insoluble in neutral and
basic solutions. However, in dilute acidic solutions pH6, the glucosamine monomers
dissociate from the polymeric chain facilitated by the protonation of the free amino
groups; solubilizing the polymer into a slightly acidic, viscous solution [93]. The pH
responsive phase change of chitosan makes it possible to process chitosan into several
forms that correspond to a host of different medical applications; examples include
tissue engineering scaffolds [94], nanoparticles [95], microparticles [96], nanofibers
[97], membranes [98, 99].
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Figure 2: process of chitin deacetylation into chitosan; chitosan is a linear polymeric
chain randomly disbursed with monomers of D-glucosamine monomers and N-acetyl-Dglucosamine [100].
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The physiological interaction between an implant and the host must be considered
during the design process, particularly so in the case of a drug delivery vehicle. One
of the most important considerations is the magnitude of the host response to the
foreign body, normally characterized by acute inflammation in almost all surgeries
involving implant. A non-degradable biomaterial will almost always require a
removal surgery, potentially with moderate risk, to avoid the inevitable foreign body
reaction from the host immune system that would end up harming the host. After the
acute inflammation stage has passed, and both the polymorphonuclear cells and
macrophages have failed to phagocytize or encapsulate the nondegradable implant in
fibrous tissue, the macrophages will begin to release reactive oxygen species (ROS)
[101]. ROS can cause significant damage to the surrounding microenvironment by
oxidizing amino acids, deactivating vital enzymes, or damaging the DNA of the
surrounding cellular population [102, 103]. Macrophages can be triggered to release
ROS in the presence of degradable implants as well, whether the implant cannot
degrade fast enough, or the degradation products might still be harmful to the host.
Chitosan can be easily metabolized by the host immune system through several
mechanisms including both chemical and physical forces breaking apart the
biopolymeric chain. The main driver of chitosan degradation is hydrolysis catalyzed
by lysozyme, an enzyme found throughout the body, including macrophages, as
detailed by Nordtveit et al. [104]. Lysozyme acts by catalyzing the hydrolysis
reaction of chitosan, cleaving the glycosidic bonds of the polymeric chain into
glucosamine and saccharide byproducts, which can be further phagocytized by or
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proteoglycans [105, 106]. There is an abundance of reports lauding chitosan for its
properties that make it an optimal biomaterial for therapeutic delivery (i.e.
biocompatible, mucoadhesive, biodegradable, antimicrobial) [90, 107]. As a naturally
derived polymer, chitosan implants provoke minimal foreign body responses;
demonstrated in a study by VandeVord et al. [108]. Porous chitosan scaffolds were
subcutaneously implanted into murine host subjects for up to 12 weeks. Authors noted
the chitosan scaffolds did not warrant any pathological inflammatory responses for the
duration of the study; evidence which further supports biocompatibility of chitosan, even
over a relatively long time period.
Chitosan is a mucoadhesive biomaterial, explained by the strong electrostatic force of
the cationic amine groups lining the backbone of chitosan to the anionic mucins,
glycosylated proteins highly concentrated on mucosal tissue surfaces such as pulmonary,
corneal, intestinal, and gastric mucosal tissues, described in a report by Karn et al. [109].
In addition to agreeing with the findings by Kart et al, Sogias et al. reported the
mucoadhesion observed in chitosan can be partially explained by the hydrogen bonding
between the chitosan and the mucosal membranes [110]. Mucoadhesion contributes to
chitosan adherence to a musculoskeletal wound via anionic molecules in the
musculoskeletal tissue, such as the anionic proteoglycans comprising connective tissue
[111].
Chitosan for Drug Delivery
Chitosan is a versatile biomaterial with many applications and forms, such as
membranes loaded with growth factors to facilitate periodontal bone regeneration [112]
and hemostatic wound dressing containing natural coagulants, used in combat trauma
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care [113]. A preliminary study of chitosan sponges loaded with vancomycin and
amikacin, revealed that both antibiotics were released at therapeutic concentrations for up
to 72 hours [25]. In several recent studies, efficacy of chitosan sponges as
biocompatible delivery devices has been demonstrated in preclinical models [25, 33,
114-116]. Chitosan sponges blended, modified, or crosslinked with composites have
shown to improve drug delivery properties of the devices, including biocompatibility,
degradation, or the antibiotic release kinetics [117-120] . A 2015 report by Parker et
al. of the addition of PEG to the formulation of chitosan sponges, loaded with
amphotericin B and vancomycin, increased degradation rates and improved the in
vitro biocompatibility compared to neutral sponges containing only chitosan [27,
121].
Another additive of interest is β-glycerophosphate (β-GP), a slightly basic anionic
molecule that creates a polyelectrolyte complex with the chitosan molecules [122].
The force of attraction resulting in the polyelectrolyte complexation between chitosan
and β-GP has been observed as similar to the interaction between chitosan and
commonly used ionic cross-linkers such as Fe(III) [123]. When formulated as a
hydrogel, chitosan and GP are very fluid, or non-viscous, at room temperature (20°C)
and as the surrounding temperature is increased to the approximate value of body
temperature (37°C) the chitosan/GP mixture undergoes a non-reversible gelation
[124]. It has been observed that as temperature increases, the ionic activity of GP
increases leading to a higher density of ionic bridges between chitosan and GP that can
explain the gelation [122, 125]. A 2007 study by Ahmadi et al. [126] investigated both
the in vitro gelation time and cytocompatibility of chitosan-GP hydrogel formulations
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characterized by varying chitosan content between 0.5-2% (wt/vol) and GP content 520% (wt/vol) in 0.1M hydrochloric acid. Results revealed as chitosan and GP content
increased, the in-situ gelation time decreased. An increase in GP content adversely
affected the in vitro cytocompatibility, while the chitosan actually improved
biocompatibility as the mass content rose to 2%. It was concluded that hydrogels
containing no more than 10% GP (wt/vol) were cytocompatible and appropriate for use
as a drug delivery system. A report by Ruel-Gariepy et al. [127] reviewed
thermosensitive hydrogels containing chitosan and GP to be implemented as drug
delivery devices. The authors deemed chitosan-GP hydrogels suitable for sustained drug
delivery based on results of drug elution profiles, noting that drug release profiles
improved with an increased GP content. The hydrogel delivery system can be loaded with
a wide range of drugs, including antibiotics, based on the fact that the electrostatic charge
of the loaded model drug compound had no effect on the release characteristics.
Additionally, authors observed the gelation rate was dependent on the temperature and on
the chitosan deacetylation degree, and the solution containing 84%-deacetylated chitosan
could be stored 3 months at 4°C without apparent change in viscosity or adverse effects
to physio-chemical properties.
Research Narrative
Over the course of recent investigations into the feasibility and refinement of chitosan
paste, clinical potential as an effective point-of-care, infection prevention tool in trauma
care has been demonstrated. Previous studies provide insight into the effect of altering
specific parameters of the paste formulation. Smith et al. detailed the original
investigation of chitosan paste [128] and demonstrated the effects of acetic acid
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concentration ((0.05M or 0.15M acetic acid) on paste properties. In vitro studies
proved that the paste made with a lower acetic acid concentration had a more effective
antibiotic elution profile, extended degradation time, as well as more favorable
injectability and adhesion qualities. However, there were major limitations in in vivo
biocompatibility; exhibited by subject morbidity in a functional biocompatibility
model involving implants in an intramuscular back model in rat subjects. The paste
formulation was changed to a 50:50 ratio of neutral to acidic chitosan components to
address compatibility issue.
A study by Rhodes et al. investigated the efficacy of a chitosan composite paste
blended with PEG and incorporated with neutral chitosan particulate [1]. The neutral
to acidic chitosan mass ratio varied among experimental groups: 2:3, 1:1, and 3:2. All
paste formulations exhibited degradation, antibiotic elution, and bio-adhesion;
however, the 2:3 neutral to acidic ratio paste was deemed significantly less
compatibility to the evaluated cell culture in vitro than the other experimental groups.
The paste proved effective in preventing bacterial contamination in a subcutaneous S.
aureus infected murine catheter model. It was concluded the paste with a 1:1 ratio of
neutralized chitosan/PEG to acidic chitosan dry mass was the optimal group for local
antibiotic delivery, based on a longer degradation time and extended elution profile
over 72 hours [1].
Beretta et al. investigated the feasibility of a completely acidic chitosan paste in
which the acetic acid concentration of the chitosan/PEG paste was solubilized in
0.85% (vol) acetic acid, as opposed to combining acidic and neutralized dry
components to reduce processing time and improve biocompatibility [36]. The fully
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acidic chitosan hydrated paste resulted in a material more homogenous than the chitosan
paste investigated previously by Rhodes et al. [1]. Additionally, the effect of changing
the ratio of chitosan to PEG was investigated by creation of experimental groups that
were made with either a 1% chitosan/1% PEG (8kDa) formulation or a 1% chitosan/0.5%
PEG (8 kDa) formulation. Results of the study indicate that an increased PEG content
significantly increases the rate of paste degradation, and therefore the rate at which
antibiotics are released. Additionally, the fully acidic paste exhibited a significantly
lower force of ejection from a modified syringe, and a decreased time of adhesion to the
tissue. The chitosan/PEG paste formulation with 1% chitosan and 0.5% PEG content was
deemed to have more suitable characteristics for a local drug delivery device.
The current report further explores the effect of different additives, acetic acid content,
as well as the incorporation of neutral chitosan particulate into the formulation. The goal
of a new paste formulation was to improve wound coverage, drug delivery
characteristics, injectability, and biocompatibility. Therefore, the formulation was
designed as an equal combination of acidic chitosan composited with a βglycerophosphate additive and neutral chitosan particulate. The addition of the
composite β-glycerophosphate to chitosan hydrogels has been shown to create a
temperature-sensitive gelation process as the temperature is increased. It was theorized
that a chitosan paste composited with β-glycerophosphate would create a thermoresponsive polymeric drug delivery system, in which the paste has a low viscosity at
room temperature and a higher, gel-like viscosity as the temperature is increased to levels
similar to the human body. A low viscosity paste is favorable for injectability from a
cannula syringe tip, and more importantly improved wound coverage; allowing the
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antibiotic loaded polymer to seep into the crevices of the complex wound bed. The
improved wound coverage decreases the distance between the antibiotics and the
bacterial contaminations, resulting in an improved antimicrobial efficacy. The model
of the drug delivery system is based off the concept of polymeric drug delivery
systems containing two types of material in which one degrades quickly and releases
the other material which degrades much slower and can deliver drugs for a longer
period of time. In an attempt to further reduce the paste toxicity, the acidic portion of
the paste was solubilized in a diluted acetic acid solution (0.5% vol.).
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Abstract
Complex musculoskeletal wounds, resultant of high-energy trauma, are a
leading cause of morbidity worldwide due, in part, to a propensity for bacterial
contamination. This work details the fabrication of a thermo-responsive,
injectable chitosan composite paste by including the additive β-glycerophosphate,
which creates a polyelectrolyte complex with the chitosan molecular backbone.
Functional and clinical efficacy evaluations as an infection prevention treatment
were determined within the scope of complex musculoskeletal wounds. Findings
from in vitro studies support the capability of chitosan paste to be loaded with
dual antibiotics for release of inhibitory levels of both amikacin and vancomycin
for at least 3 days. Further, rates of enzymatic degradation of approximately 60%
of the initial mass were observed within 7 days. The cytocompatibility of the
thermogel is an area which requires improvement; eliciting the lowest cell count
among all experimental groups, approximately 77% of the Control Chitosan
Sponge group. The thermogel ejection force, approximately 20N, is significantly
lower than comparable, previously studied paste formulations. A preclinical,
compatibility study of thermogel exposed to both hard and soft tissues
demonstrated the paste to be capable of implantation for up to 7 days, inducing
inflammatory responses similar to previously studied chitosan pastes. In the
murine, polymicrobial defect model, the average CFUs retrieved from explants in
the thermogel group was lower when compared to control, although no significant
differences were present in bacterial clearance rate. Results indicate the thermogel
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is a compatible, degradable biomaterial capable of therapeutic, local antibiotic release for
up to 7 days.

Keyword: chitosan, local antibiotic delivery, biofilm, complex musculoskeletal
wounds, trauma care
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Introduction
High-energy trauma to the musculoskeletal system can cause a complex wound
characterized by lacerations and abrasions, open fractures, hematoma formation, and
tissue necrosis [2-6]. The World Health Organization estimates traumatic injuries to
the musculoskeletal system are the fourth leading cause of morbidity worldwide,
responsible for five million annual fatalities [7, 8]. Unfortunately, the incidence of
traumatic musculoskeletal injuries and accompanying morbidity is growing as the
unsafe use of motorized vehicles increases in third-world and developing countries.
Consequently, 95% of deaths related to traumatic injuries occur within low or middleincome countries [7]. Reports have estimated if trauma care in under-developed
socioeconomic countries was as established in “high income” countries, then two
million lives could potentially be saved each year. Even, a more conservative
estimate states an 8% improvement in injury mortality rates in low and middle
income countries would result in 400,000 lives saved annually [9].
Complex musculoskeletal wounds are highly susceptible to bacterial
contamination, with infection rates ranging from 20% of civilian injuries [10-12] to
65% of orthopaedic trauma suffered [11, 13]. Necrotic tissue surrounding the wound
experiences a diminished perfusion of bodily fluids, effectively restricting leukocytes
and IV antibiotics from accessing the wound via vascular pathways. The wound
forms a sheltered, anaerobic environment favorable for bacterial proliferation [6].
Furthermore, the complex morphology of a severe musculoskeletal wound can create
a high surface area easily allowing for the adherence of invading planktonic bacteria,
the initiating mechanism in the transformation to biofilm, which can be resistant to
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antibiotics [14-16]. Biofilm-forming bacterial strains (i.e. Staphylococcus aureus,
Pseudomonas aeruginosa) are among the most commonly identified species in
complex musculoskeletal infections [17, 18]. Some biofilm-containing infections can be
eradicated with antibiotics administered systemically, but at dangerously high
concentrations. Antibiotics can cause harm to the patient at high concentrations
including nephrotoxicity and ototoxicity, among other ailments [19]. Local delivery
devices used as an adjunct to the standard prophylactic antibiotics may provide biofilmeradicating levels of antibiotic to local tissue without systemic concentrations reaching
dangerous levels [20-23].
The natural biopolymer chitosan, comprised of randomly dispersed glucosamine and
N-acetyl glucosamine monomer units linked by glycosidic bonds in a β(1-4) pattern [24],
demonstrates favorable characteristics for local drug delivery, including compatibility,
and bio-resorbable nature. Additionally, many material characteristics such as
degradation or drug release are tailorable by altering the crystallinity, molecular weight,
degree of deacetylation of chitosan, as well as chemical or physical crosslinking of
synthetic additives [25-27]. Lyophilized chitosan sponges are capable of local,
therapeutic antibiotic release [28-33]but have limited ability to conform to complex
morphologies, as well as an initial burst release of the loaded antibiotics [34, 35].
To address the limitations of chitosan in a sponge form; an injectable, paste variation
of finely ground, lyophilized chitosan hydrated with antibiotic loaded saline has been
developed and shown potential as an effective infection-prevention tool within
musculoskeletal wound trauma care [1, 36].

By modifying the paste composition to

include beta-glycerophosphate (β-GP) a thermogel material can be formed [35]. Neutral,
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lyophilized chitosan particulate is incorporated into the formulation in an attempt to
improve the biocompatibility and drug release characteristics of the paste; qualities
described in a report by Rhodes et al. [34].
The goal of the work reported in the current study is to develop an infectionprevention tool to be used in trauma care; effectively reducing the incidence of
morbidity associated with musculoskeletal wounds resultant of traumatic injuries. It
is hypothesized thermogel chitosan paste formulation will form a biocompatible; bioresorbable; temperature-responsive drug delivery polymer; capable of point-of-care
antibiotic loading via hydration with antibiotic loaded saline and local, therapeutic
release in vivo for at least 72 hrs. The objective of this study is to determine
preclinical efficacy of thermogel paste, including cytocompatibility, antibiotic release
characteristics, enzymatic degradation, and injectability. Preliminary in vivo efficacy
of the paste is evaluated via preclinical studies of functional compatibility and
antimicrobial efficacy over a 7-day time period.
Experimental
2.1 Materials
Chitopharm™ S chitosan powder (825±1.7 % DDA, 251 kDa) is produced by
Chitopharm (Tromsø, Norway). Poly(ethylene-glycol) (8kDa), vancomycin,
amikacin, and Avertin (2, 2, 2-Tribromoethanol) are from Sigma Aldrich (St. Louis,
MO, USA). β-Glycerophosphate, Disodium Salt, Pentahydrate (β-GP), (306.1Da,
CAS 13408-09-8 Calbiochem), as well as the dialysis membranes (pore diameter
100µm) used in the elution studies are from EMD Millipore (Billerica, MS, USA).
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The 4.5L benchtop lyophilizer is made by LabConco (Kansas City, MO, USA).
Phosphate buffered saline, Cellgro Dulbecco’s modified eagle medium containing Lglutamine and sodium pyruvate, fetal bovine serum, high performance liquid
chromatography (HPLC) mobile phase components, and the spectrofluorometric
amikacin detection method reagents are purchased via Fisher Scientific (Hampton, NH,
USA). Normocin is acquired from InvivoGen (San Diego, CA, USA). NIH3T3 cells, as
well as the bacterial strains of Staphylococcus aureus (ATCC #12598) and Pseudomonas
aeruginosa (ATCC #27317) are supplied by the America Type Culture Collection
(Manassas, VA, USA). The Cell Titer-Glo® assay is manufactured by Promega
(Madison, WI, USA). The Synergy™ H1 plate reader is made by BioTek, (Winooski,
VT, USA). The Dionex UltiMate 3000 HPLC, the Hypersil Gold C18 column for
vancomycin detection, as well as the 125-mL plastic Nalgene® containers are purchased
from Thermo Fischer Scientific (Waltham, MA, USA). The lysozyme enzyme (Type
VI) is purchased from MP Biomedicals (Santa Ana, CA, USA). Metal, porous
hemispheres from Norpro (Everett, WA, USA). The small bore (diameter 2mm) 10mL
syringes are from BD™ (Franklin Lakes, New Jersey, USA). The large bore syringes
(7mm diameter) are from Qosina (model C1105; Ronkonkoma, NY, USA). The
compressive strength testing machine (Instron 33R Universal Testing Machine 4465, 5kN
load cell) and operating software (Bluehill v2.13) are products of Instron (Norwood, MA,
USA). The male Wistar rats, strain code 003, are from Charles River North America
(O’Fallon, MO, USA). Gelfoam® porcine gelatin sponges are products of Pfizer
Manufacturing (Puurs, Belgium). Rimadyl is purchased from Zoetis (Parippany, NJ,
USA). The OSTEO16 imaging software is a product of BIOQUANT (Nashville, TN,
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USA). The histology scanner and microscope camera are manufactured by Nikon
Instruments Incorporation (Melville, NY, USA). ImageJ image analysis software, as well
as 6 week old male mice C57BL/6 are supplied by the National Institute of Health
(Rockville, MD, USA). Graphical representations and statistical analysis of data is
performed via GraphPad Prism 7.2, a program created by GraphPad Software
Incorporation (La Jolla, CA, USA).
2.2 Fabrication
The experimental and control groups of antibiotic delivery devices are
characterized by the content of chitosan, additives, acetic acid solution, as well as the
presence of a neutralization step (Table 1). The chitosan paste formulation
containing β-GP, termed “thermogel”, is evaluated with respect to control groups of
neutral, lyophilized chitosan. For the cytotoxicity, antibiotic elution, and enzymatic
degradation studies the neutral chitosan control group was investigated in two forms:
lyophilized sponge coupons (8mm diameter) referred to as “Control Sponge” (Fig.
1D) and a particulate made from finely ground lyophilized sponges named “Control
Particulate” (Fig. 1E). A chitosan paste composited with poly(ethylene-glycol)
(PEG) is included in studies as a benchmark control group, as it was previously
evaluated in a report by Berretta et al. [33].
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Table 1: Experimental chitosan group formulations.
Experimental Group

chitosan (wt)

acetic acid (vol)

additive (wt)

pH

1. Control Chitosan

1%

1%

-

neutral

2. PEG paste

1%

0.85%

0.5% PEG

acidic

10% β-GP

acidic

50%

Control Chitosan Particulate

50%

2%

3. Thermogel
0.5%
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Figure 1A-F: Flowchart detailing the fabrication process of chitosan drug delivery
devices; A. chitosan being solubilized in acetic acid solution; B. chitosan sponges rinsing
with deionized water and pH monitoring during neutralization process; C. chitosan cast
molds being lyophilized into sponges; D. neutral chitosan sponge (left), finely ground
chitosan particulate (right); E. hydration of paste via antibiotic-loaded saline; F. chitosan
paste being ejected from a small-bore syringe.
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Control chitosan sponges were fabricated by dissolving 1g of chitosan in 100mL of
aqueous solution containing 1% (vol.) acetic acid. After mixing, solution was cast and
frozen overnight at -80°C, and then lyophilized in a 4.5L benchtop lyophilizer at -50°C,
with a minimum vacuum pump displacement of 86L/min (Fig. 1C). At this step,
lyophilized sponges are highly porous and solubilize in aqueous environments into a
slightly acidic solution, referred to in the report as “acidic” chitosan
A portion of the acidic sponges are then neutralized via an acid-base reaction
described by Rhodes et al. [34], in which a strong base donates an electron to the
protonated amine groups constituting the chitosan backbone. The sponges are again
frozen overnight at -80°C then lyophilized into the control neutral lyophilized sponge,
which is then ground into a particulate form. Hydration of the control groups requires
120mg of dry mass mixed with 1mL of PBS.
The thermogel chitosan paste formulation was fabricated by combining equal parts
acidic, thermo-responsive chitosan composited with β-GP and neutral chitosan particulate
described previously. Fabrication of the acidic portion of the thermogel sponges were
fabricated by dissolving 10g of β-GP and 2g of chitosan in 100mL aqueous solution of
0.5% (vol.) acetic acid. The solution ws then cast into molds, frozen overnight at -80°C,
lyophilized, and ground into particulate via a blade grinder. Prior to hydration, the acidic
and neutralized chitosan components are combined in a 1:1 ratio by dry mass. The
thermogel is hydrated at the same ratio as the control groups, 120mg of dry mass per
1mL of PBS. The resultant paste is a temperature sensitive polymer with a very low
viscosity at room temperature (20°C), and as the surrounding environment increases to
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approximately body temperature (~37°C), it undergoes a gelation process, resulting
in a more viscous paste material.
The PEG Paste is a benchmark experimental group previously investigated by
Berretta et al. [33]. Briefly, 500mg of PEG and 1g of chitosan was dissolved in
100mL of 0.85% (vol.) acetic acid. Freezing and grinding were conducted in a similar
manner to other groups. PEG Paste was hydrated by mixing 133mg of dry mass with
1mL of PBS; resulting in a homogenous, acidic paste, as it does not undergo the
neutralization process as the control groups do.
2.3 Cytocompatibility
In a cytocompatibility model described by Parker et al. [36], NIH3T3 cells were
seeded onto a 24-well plate at a density of 2*104cells/cm2 in 1mL of cell culture media
consisting of High Glucose Dulbecco’s Modified Eagle Medium, 10% (vol.) fetal
bovine serum and 0.1 mg/mL Normocin. Twenty-four hours post seeding, cell culture
media was gently aspirated and replaced with 1 mL of fresh culture media. The
Control Sponge and Particulate (120mg), PEG Paste (133mg), and thermogel (120mg)
samples hydrated with 1mL of sterile filtered phosphate buffered saline (PBS, 1X) are
added to porous (diameter 8µm) cell culture inserts (n=3, diameter 8µm), placed in the
wells seeded with the NIH3T3 cells, and incubated (37ºC) for 72 hours.
The viability of NIH3T3 cells was quantified via the Cell Titer-Glo® assay, and
normalized to known cell concentration.
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2.4 Antibiotic Elution and Activity
Experimental samples (n=3, 133mg PEG Paste, 120mg Control Sponge, Control
Particulate, thermogel) were hydrated with 1mL of sterile 1X PBS loaded with
vancomycin (10mg/mL) and amikacin (10mg/mL). Samples were inserted into cell
culture crowns fitted on the bottom with dialysis membranes (diameter 100µm) and
submerged in 8mL of sterile 1X PBS in a 6-well cell culture plate (Fig. 2), and gently
shaken in an incubator at 37°C throughout the 7-day study. Eluate samples (2mL) were
collected every 24hrs and frozen (-80ºC); the remaining elution solution was gently
aspirated and replaced with 8mL of sterile 1X PBS.
Vancomycin levels in the eluate samples were measured via HPLC in a method
derived from multiple glycopeptide detection protocols [37-39]. Peaks were detected at
250nm UV, with a retention time of 1.6 min, using a C18 column 150mm x 4.6mm
column in a mobile phase of 70% phosphate buffer (0.124M KH2PO4 and 0.08M
K2HPO4) and 30% acetonitrile (CH3N) at a flow rate of 1 mL/min.
Amikacin concentrations were measured using a spectrofluorometric protocol to detect
aminoglycosides, described by Omar et al. [40]. Briefly, eluate samples were diluted tenfold, and reacted with a reagent of acetylacetone and formaldehyde in a buffer solution
containing boric, acetic, and phosphoric acid titrated to a pH of 2.7. The absorbance
values of the reacted product at 450nm were measured with a SynergyTM H1 plate reader
and calibrated to known amikacin concentrations. The measured antibiotic concentration
of the eluates is supported via zone of inhibition (ZOI) analysis, following a protocol
described by Ericcson et al. [41]. S. aureus and P. aeruginosa are chosen as
representative bacterial strains because they are among the most commonly detected
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bacterial strains in infected musculoskeletal wounds, and capable of forming biofilm
[42]. Trypticase soy broth (TSB) agar plates were inoculated with either Staphylococcus
aureus (ATCC 12598) or Pseudomonas aeruginosa (ATCC 27317). Blank paper
discs (diameter 6mm) were hydrated with antibiotic eluate samples (30μl), placed on
the inoculated TSB agar plates, and incubated (37°C) overnight. Plates were imaged,
and the ZOI diameters, excluding disc diameter, were measured via the ImageJ
software.
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A

B

Figure 2A-B: Depiction of antibiotic elution study setup featuring a 6-well plate filled
with PBS and cell crown inserts containing the hydrated experimental samples.
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2.5 Degradation
The degradation characteristics of the thermogel chitosan paste are assessed as the
reduction in the dry mass during submersion in a lysozyme solution over a 7 day
durations, based on the enzymatic degradation of chitosan by lysozyme [43]. The
initial dry mass of experimental samples was recorded, (n=3/time point; 240mg
Control Sponge, Control Particulate, and thermogel samples, 267mg PEG paste). The
samples were hydrated with 2mL of PBS; placed in porous (diameter 1.5mm), metal
hemisphere containers; and restrained to the containers via a para-film cap sealing the
container opening. The porous vessels containing the experimental samples are
submerged in 40mL of lysozyme solution (Lysozyme Type IV, 1mg/mL), para-film
side down in 125-mL plastic Nalgene® containers, and gently shaken in an incubator
(37°C) for the duration of the study. Every 48 hours, the lysozyme solution was
gently aspirated from the containers and completely replaced. On days 1, 3, 5, and 7
the experimental samples (n=3/time point) were retrieved from the solution, dred
overnight in a vacuum oven (80°C), and the mass was recorded. Percent of initial mass
remaining was calculated via equation (1).
Final Sample Mass (mg)

Percent of Initial Mass Remaining (%) = Initial Sample Mass (mg) × 100
(1)
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A

B

Figure 3A-B: (A) degradation model materials including the porous hemisphere, parafilm cover, and 125mL containers; (B) experimental sample in porous hemisphere
submerged in lysozyme solution.

44

2.6 Injectability
The force of ejection was assessed by ejecting 5mL experimental samples
(n=3) of the PEG paste (667mg) and thermogel paste (600mg) from a 10mL syringe
(bore diameter 2mm) and a 15mL large bore syringe (diameter 7mm). Syringes were
fixed in a compression testing machine depressing the plunger at a rate of 1mm/sec
until the paste was completely ejected (Fig. 4A-B). The injectability was quantified as
the maximum reactive force of the syringe plunger against the compressive load cell
as the 5mL paste samples are ejected. As a benchmark value to represent a relevant
ejection force, volunteers (n=10) were asked to depress the plunger of a 10mL syringe
modified with a load cell to measure the pressure. The benchmark value of ejection
force was then assessed as the average of force applied to the syringe plunger.
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A

B

Figure 4A-B: Experimental paste samples being ejected from (A) the small-bore syringe
and (B) the large-bore syringe.
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2.7 Preclinical, Functional Model of Compatibility
Animal Care and Use Statement: Study protocols were approved by the University
of Memphis IACUC protocol #0758. All appropriate measures were taken to
minimize pain and discomfort.
Male Wistar rats were subject to a surgical procedure to create an orthopaedic
defect superficial to the tibial tuberosity and expansion of a femoral muscular pouch in
which experimental implants were inserted. The study observed 5 groups: a positive
control group of rats which receive the same orthopaedic defect but no implant (n=3),
Control Sponge coupons (n=3, 24mg), Gelfoam® gelatin sponges (n=6, 24mg), PEG
paste (n=6, 26mg), and the thermogel paste (n=6, 24mg). Prior to implantation,
implants are hydrated with sterile 1X PBS (200µl).
The rat subjects were anesthetized using isoflurane inhalation. Right hind limbs
were shaved and cleaned with betadine; and a 1mm deep incision of approximately
5mm in length were made superficially to the tibial tuberosity via a No. 10 scalpel
blade, exposing the femoral epicondyle and proximal tibia head (Fig. 5A). An
abberation was made with the scalpel to increase the hard tissue surface area exposed
to the implant and as an identification marker for later histological processing (Fig.
5B). Using surgical scissors, a muscular pouch was formed within the adductor
muscular group in the medial lower thigh of the rats. The chitosan sponge and
Gelfoam® samples were then inserted via tweezers and the chitosan paste injected via
a 1mL tuberculin syringe (Fig. 5C-D). Two subcutaneous sutures sealed the muscular
pouch and the incision closed with 2 staples. The subjects were administered
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subcutaneous injections (0.1mL) of Rimadyl 24hr and 48hr post-surgery for pain
management.
Rats were euthanized at 7 days via carbon monoxide asphyxiation, the right hind
limbs excised and preserved in a 10% neutral formalin solution for a minimum of 14 days
before histological processing. The tissue samples were decalcified and embedded in
paraffin. Longitudinal sections were cut in the sagittal plane of the limb samples with an
approximate thickness of 5µm, then stained with hematoxylin and eosin. High resolution
montages of the stained tissue sections, fixed to histology slides, were created via a
Nikon inverted microscope Eclipse TE300 operated by BIOQUANT OSTEO16 imaging
software (Fig. 5E). Qualitative histological analysis of the montages was performed by
blinded reviewers (n=9) evaluating the inflammation based on the Knodell histologic
activity index [45] and modified by Parker et al. [46]. The inflammation score range
from 0 to 5: minimal to no inflammation received a score of 0; 1 for the presence of very
mild cellular aggregation; 2 represents a moderately elevated level of cellular aggregation
immediately surrounding the implant; 3 for a wider, darker ring of cellular aggregation
surrounding the implant; 4 for moderate to acute cellular aggregation in a thicker layer
surrounding the implant; and 5 for severe cellular aggregation as well as fibrous tissue
formation encapsulating the implant.
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Figure 5 A-E: Wistar rats are implanted with experimental samples to observe the
correlation between the implant formulation and the inflammatory response; A. a 1 cm
incision exposes the anterior tibia head; B. a bone defect was applied; C. a control sponge
coupon is inserted into the intramuscular pouch; D. paste samples are subcutaneously
injected; E. After 7 days, the rats are sacrificed, limbs explanted, and tissue undergoes
histological processing to detect the inflammatory response.
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2.8 Preclinical, Infected, Functional Model of Antimicrobial Efficacy
Animal Care and Use Statement: Study protocols were approved by the University of
Arkansas School of Medical Sciences IACUC protocol #3579. All appropriate measures
were taken to minimize pain and discomfort.
Five experimental groups of murine subjects (n=5) were inoculated with a
polymicrobial infection of S. aureus and P. aeruginosa. The infected functional model is
adapted from a protocol reported by Bernthal et al. [50] and has been implemented to
assess the efficacy of antibiotic-loaded chitosan paste in a report by Beretta et al [33].
The murine subjects received isoflurane inhalation anesthesia and Avertin (400-600
mg/kg). The left hind limb shaved and antiseptically cleaned with povidone iodine and
70% ethanol. An incision of approximately 5mL in length and 1mL in depth was made
superficially to the patella, exposing the femoral epicondyle. A 26-gauge needle was
bored into the exposed femoral epicondyle, then further expanded with a 23-gauge needle
(Fig. 6A). The inoculation media consisted of 104 colonies of S. aureus (UAMS-1) and
104 colonies of P. aeruginosa (ATCC 27317) suspended in 2 μl of phosphate buffered
saline. Inoculum was injected into the newly formed intramedullary cavity. A stainless
steel Kirshner wire (1cm) was then inserted into the intramedullary cavity (Fig. 6B-C).
Subjects belonging to group 1, the negative control group, received no form of
prophylaxis at all. Group 2 was administered antibiotics systemically via an
intraperitoneal injection of the antibiotic-loaded PBS (100µl) containing vancomycin
(10mg/mL) and amikacin (10mg/mL) post-surgery. The third experimental group was
treated with neutral chitosan sponge coupons (diameter 8mm, 20mg) hydrated with the
same antibiotic-loaded PBS (100µl) as the previous group, then inserted adjacent to the
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orthopaedic implant at the distal base of the femur. The thermogel experimental paste
(24mg) and PEG paste (26mg) samples were hydrated (100µl) with the antibiotic-loaded
PBS containing vancomycin (10mg/mL) and amikacin (10mg/mL) then injected into
the subcutaneous pouch surrounding the infected intramedullary implant (Fig. 6D).
Following administration of each form of prophylaxis, the surgical site was sutured,
and the mice were monitored for 7 days before being sacrificed via carbon monoxide
asphyxiation. The left hind limb is explanted, and the k-wires removed. The k-wires
retrieved from each group were used to detect the presence of bacterial CFUs. The kwires were sonicated in sterile PBS, serially diluted, and plated on TSB agar plates.
The explanted thighs are removed of soft tissue, minced, homogenized, and diluted in
a sterile saline solution, plated on a TSB agar plate. The bacterial CFUs formed from
the tissue homogenate and k-wire dilutions are then quantified after 24 hours in an
incubator (37°C).
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Figure 6: (A) needle bored into murine femoral epicondyle; (B) insertion of k-wire into
intramedullary cavity; (C) X-ray image of explanted limb illustrating implant location;
(D) injection of approximately 100µl of chitosan paste into infected, orthopaedic surgical
site.
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2.9 Statistical Analysis
For all applicable data, normality was determined via the Shapiro-Wilk test. To
detect significant differences in the data retrieved from the cytocompatibility and
injectability studies, an ordinary one-way Analysis of Variance (ANOVA) followed
by Holm-Sidak’s post-hoc analysis to detect differences among experimental groups.
Data from the in vitro antibiotic elution and enzymatic degradation studies were
analyzed via a two-way ANOVA followed by Holm-Sidak’s post-hoc analysis to
identify significant differences with both time and experimental group as factors.
Where applicable, all graphical results are presented as the average ± standard
deviation.
Data gathered from the in vivo models of functional compatibility and
antimicrobial efficacy can be considered non-parametric and analyzed accordingly.
The inflammation scores from the rat compatibility study, as well as the bacterial
CFU counts and infection clearance rates from the infected orthopaedic study do not
exhibit a Gaussian population distribution. Statistical analysis is performed via the
Kruskal-Wallis one-way analysis of variance test followed by Dunn’s multiple
comparisons test to identify statistical differences among all experimental groups. A
statistical significance level of α=5% is applied to all statistical analyses.
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Results and Discussion
3.1 Cytocompatibility
The thermogel elicited a viability response not significantly different from the Control
Sponge group (p<0.003), with average cell counts of approximately 1.0*105 and 1.3*105
respectively. However, the thermogel exhibited significantly lower cytocompatibility
than the PEG Paste (p<0.003) and the Control Particulate samples (p<0.001) (Fig. 7).
Although the thermogel elicited the lowest average cell count among all experimental
groups, a cellular response similar to the Control Sponge group is a positive finding, as
the cytocompatibility of chitosan has been well documented [51]. Ahmadi et al. reported
on the cytotoxic response of fibroblast cells exposed to chitosan hydrogels composited
with β-GP [35], concluding a chitosan hydrogel with a β-GP content of no more than
10% (wt.) does not pose major cytotoxicity threats, allowing it to be used as a therapeutic
delivery device. It is possible that lowering the content of β-GP would improve the
cytocompatibility of the thermogel experimental paste. The favorable NIH3T3 viability
response elicited by the PEG Paste, compared to the thermogel was expected; as the
cytocompatibility benefits of adding PEG to chitosan have been well documented. The
presence of PEG has been shown to lessen the cytotoxicity of lyophilized chitosan
sponges [30, 36], hydrogels [52-54], and chitosan paste formulations [33, 34].
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Figure 7: Viability response of NIH3T3 cells after 72h of indirect exposure to the control
and experimental chitosan samples (n=3); data is presented as the average cell count ±
STD; * represents a significant difference against all groups (p≤0.0001); # represents a
significant difference among the thermogel and PEG Paste groups (p<0.003).
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3.2 Antibiotic Elution and Activity
Thermogel released both amikacin and vancomycin at infection-inhibiting levels for at
least 72 hours in all evaluations of the in vitro model, including the antibiotics elution
profiles (Fig. 8) and corresponding ZOI analysis of the eluate samples (Table 2.2). The
pairing of the thermogel chitosan paste formulation and amikacin presents the most
effective drug release profile, releasing at levels therapeutically effective against P.
aeruginosa for 4 days. Vancomycin is released from the thermogel device at levels
comparable to the PEG Paste, detected for up to 5 days, and active against S. aureus
through 72hr based on ZOI analysis.
The thermogel chitosan paste samples released amikacin at concentrations
significantly higher than the PEG Paste and Control Particulate groups on Day 1
(p<0.019), and highest among all groups on Day 2 (p<0.05). The thermogel group
demonstrated the most prolonged antimicrobial efficacy against P. aeruginosa, through
day 4. With reported minimum inhibitory concentrations (MIC) of approximately 14
µg/mL [59, 60], findings support the favorable amikacin elution profile.
On Day 1, the Control Sponge group released vancomycin at a significantly higher
concentration than all other chitosan paste groups (p<0.05). There were no significant
differences detected after Day 1, but thermogel displays an extended elution time
comparable to the PEG Paste group. The Control Particulate and PEG Paste eluates
inhibit the growth of S. aureus through Day 4, the longest time of activity. With a MIC
of approximately 1-2µg/mL [61, 62], the thermogel eluate samples proved effective in
inhibiting microbial growth through Day 3.
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The elution profiles of both antibiotics illustrate an initial drug burst release from
all experimental groups. Initially, both amikacin and vancomycin were released from
the Control Sponge group at higher concentrations than the thermogel. As the study
progressed the thermogel demonstrated a prolonged release of the antibiotics at
therapeutic levels, while the Control Sponge purges all loaded antibiotics by Day 2.
The in vitro elution profiles of vancomycin for the thermogel and PEG Paste are in
agreement with those reported in studies of other chitosan drug delivery systems
blended with composites. A study by Berretta et al. [33] of chitosan pastes blended
with a varying PEG content investigated the amikacin and vancomycin elution profiles
of the scaffolds, concluding all chitosan paste blends eluted both antibiotics at
therapeutic levels for at least 72 hours. The antibiotic release profiles of the thermogel
paste are comparabale to the favorable drug release characteristics studied in a report
by Ruel-Gariepy et al. of temperature-sensitive drug delivery systems consisting of
chitosan hydrogels composited with β-GP [63]. The authors note the chitosan drug
delivery systems are capable of being loaded with a wide range of drugs, including
antibiotics. As amikacin is an aminoglycoside, electrostatic forces of attraction among
the polyelectrolyte complex of chitosan and β-GP and the positively charged amine
groups of amikacin could be a reason for the favorable pharmacokinetics of the
pairing; similar to the electrostatic forces which bind the antibiotic to the ribosomal
structures of bacteria [64].
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Figure 8: Concentrations of (A) vancomycin and (B) amikacin measured in eluate
samples (n=3) gathered over a 7-day study, data is presented as the average concentration
of the eluate solution ± STD. * represents a concentration significantly higher than all
other groups at the time point (p<0.05)
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Table 2.1 Serial dilution of antibiotic concentrations as a standard for zone of inhibition
analysis; green represents the presence of a zone of inhibition while red represents no
antimicrobial efficacy.
A. Staphylococcus aureus Zone of Inhibition Diameter (mm)
Antibiotic
(µg/mL)

10000

1000

100

10

1

Vancomycin

9.4

7.1

3.6

1.7

0

Amikacin

13.7

9.4

2.5

0.4

0

Combination

12.4

7.4

3.5

0

0

B. Pseudomonas aeruginosa Zone of Inhibition Diameter (mm)
Vancomycin

0

0

0

0

0

Amikacin

19.8

12.4

5.1

0

0

Combination

18.9

11.9

3.6

0

0

Table 2.2 Zone of inhibition diameters formed from eluate samples from elution study.
A. Staphylococcus aureus Zone of Inhibition Diameter (mm)
Antibiotic Eluate Time Point (day)
Group
1

2

3

4

5

6

7

1. Control Sponge

11.6

7.1

2.9

0

0

0

0

2. Control Particulate

12.5

7.7

6.2

2.6

0

0

0

3. Thermogel

10.9

6.8

4.2

0

0

0

0

4. PEG paste

8.9

7.9

5.6

1.9

0

0

0

B. Pseudomonas aeruginosa Zone of Inhibition Diameter (mm)
1. Control Sponge

12.7

8.2

0

0

0

0

0

2. Control Particulate

12.4

9.7

2.5

0

0

0

0

3. Thermogel

12.1

9.6

2.8

1.5

0

0

0

4. PEG paste

10.8

8.6

3.7

0

0

0

0
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3.3 Degradation
The thermogel and PEG Paste groups demonstrated a significantly higher degradation
rate than the Control Sponge and Particulate groups based on the percentage of initial
mass remaining at every sample time point (p<0.0001). Just after 24 hours, the
thermogel and PEG paste samples were reduced to approximately 55% and 60% of the
initial mass respectively. There were no significant differences in the rate of enzymatic
degradation among the PEG Paste and thermogel groups at any time point during the
study (Fig. 9). The Control Sponge and Particulate groups displayed a minimal massbased reduction over the 7-day study; retaining approximately 100% to 75% of the
original mass, respectively. There was no significant difference in percentage of initial
mass remaining among the control groups on days 1, 3, and 5. However, on Day 7 the
percentage of initial mass remaining of the Control Particulate was significantly lower
compared to the Control Sponge (p<0.002).
The notable difference in degradation among the Control Sponge and Control
Particulate Groups on Day 7 can be attributed to the increased surface area of the
Chitosan Paste group. As chitosan scaffolds swell in aqueous solutions, enzymes can be
restricted from freely transporting into the matrix; causing surface erosion to be the
primary degradation mechanism in smaller chitosan implants. The differences in
degradation support the claim that the degradation rate of lyophilized chitosan is
proportional to its surface area [56, 57].
The acidic chitosan in the experimental paste formulations can be a factor increasing
hydrolytic degradation. The protonated amine group of acidic chitosan dissociates from
the chitosan molecule in aqueous solutions; facilitating the solubilization of the chitosan
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molecules [21]. Rhodes et al. studied the in vitro degradation of chitosan-PEG
blended pastes formulated in varying ratios of acidic to neutral chitosan. It was noted
the degradation rate increased with an increased acidity of the chitosan paste
formulation [34]. The paste groups were degraded to approximately 10-30% of their
initial mass after 6 days, comparable value to the chitosan paste groups in the current
study where the thermogel degraded to approximately 40% of the initial mass after 7
days of lysozyme-based degradation.
An increased surface area may also contribute to the chitosan paste degradation as
well. Additionally, composite materials in blends may also contribute to degradation.
Composite chitosan scaffolds created from a physical blend, such as the PEG Paste, or
a weak polyelectrolyte complex such as the thermogel, are more susceptible to
hydrolytic degradation than chitosan-only constructs, promoting the overall rate of
degradation of the construct [65, 66]. The addition of PEG causing an increased
degradation rate in chitosan constructs has been demonstrated previously in a study by
Parker et al. [67].
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Figure 9: Enzymatic degradation of experimental chitosan samples (n=3) over the 7-day
study, data is presented as the average percent of the initial mass ± STD; * represents a
significant difference in percent of initial mass remaining compared to both the Control
Sponge and Particulate groups (p<0.0001); # represents a significant difference in
percent of initial mass remaining between the Control Sponge and Particulate groups,
(p<0.002).
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3.4 Injectability
For both variations of syringe bore diameter, the thermogel exhibited a reactant
force of ejection comparable to the PEG Paste, and well below the average measured
force of ejection exerted by volunteers on the syringe modified with a load cell. For
both the thermogel and PEG paste, the small-bore syringe (diameter 2mm) required a
significantly higher ejection force than the large-bore syringe (diameter 7mm)
(p<0.002). It is worth noting the thermogel displayed a consistency with a very low
viscosity and the test was performed at room temperature (20°C).
Findings are in agreement with previous research into the injectability of chitosan
paste, such as the ejection forces reported in a study by Berretta et al. of chitosan
pastes blended with PEG being ejected from a large-bore syringe [33]. In the study,
the PEG Paste was tested alongside another chitosan paste which had a 1:1 mass ratio
of neutral chitosan to acidic chitosan composite, similar to the thermogel formulation
in the current study. A potential benefit of adding β-GP to the chitosan paste
formulation is improved injectability, due to the low viscosity of the paste at room
temperature (20°C). The authors of a study of thermo-responsive drug delivery
systems noted the chitosan/β-GP mixtures displayed a liquid-like behavior at low
temperatures before undergoing a gelation process at higher temperatures [68].
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Figure 10: Injectability of the experimental paste samples (n=3) from syringes with tips
of large diameter (LD) and a small diameter (SD), compared to a benchmark value for a
comfortable force of ejection; data is represented as the average ejection force ± STD; *
represents a significantly higher force of ejection between bore diameters (p<0.002)
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3.5 Preclinical, Functional Model of Compatibility
Based on the results of qualitative histological analysis of the degree of
inflammation, the PEG paste elicited the highest inflammatory response among all
experimental groups. The PEG paste (p<0.0001) and thermogel (p<0.027) provoked
an inflammatory response significantly more severe than the Control Sponge, the
Gelfoam® gelatin sponge, and the No Implant control groups. There is no statistical
difference between experimental groups (p<0.073), although the PEG Paste scored a
slightly higher average inflammation level than the thermogel, with scores of
approximately 3.5 and 2.9 respectively. Compared to the subjects which did not
receive implants, there was no statistical difference in the level of inflammation
elicited by the Control Sponge samples, or the Gelfoam® gelatin sponge (p≥0.08)
(Fig. 11).
The inflammation elicited by the Control Sponge was not significantly different
from the Gelfoam® and No Implant groups. As a naturally-derived polymer, chitosan
provokes a minimal foreign body response. A characteristic which is supported by the
results of the current study and many more publications reviewing studies of the
foreign body response to chitosan implants [58, 69, 70]. One example is a study by
VandeVord et al., in which authors investigate the foreign body reaction to lyophilized
chitosan sponges implanted subcutaneously into murine host subjects for up to 12
weeks. No pathological inflammation in response to the chitosan was detected for the
duration of the study [71].
The increased level of inflammation caused by the thermogel and PEG paste is
potentially a result of the dissolution of the acidic chitosan components, decreasing the
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pH of the tissue and bodily fluids immediately surrounding the implant. Also, an
increased surface area may attract activated macrophages which secrete reactive
oxygen species capable of causing local acidosis [72, 73]. It has been noted that as the
microenvironment surrounding an implant becomes more acidic the inflammatory
response to the implant is more severe, and acidic chitosan will degrade at an increased
rate [74-76]. The thermogel may provoke a lower inflammatory response than the PEG
Paste due to the presence of the neutral chitosan, as well as the basic β-GP additive which
can potentially buffer acidosis [68]. The inflammation scores of the thermogel and PEG
paste groups are comparable to the results from similar studies of in vivo compatibility of
chitosan blended with PEG in lyophilized sponge form by Parker et al. [129], as well as
in a paste form by Rhodes et al. [1]. In both sponge and paste form, the acidic chitosan
modified with composites produced more inflammatory response than the control neutral
chitosan sponges.
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Figure 11: Histologic analysis results presented as a 5-95 percentile box and whisker plot
of the average inflammation score with the mean represented as (+); the inflammation
score ranges from 0 to 5: minimal to no inflammation receives a score of 0; a 1 for the
presence of very mild cellular aggregation; a 2 represents a moderately elevated level of
cellular aggregation immediately surrounding the implant; a 3 for a wider, darker ring of
cellular aggregation surrounding the implant; a 4 for moderate to acute cellular
aggregation in a thicker layer surrounding the implant; and a 5 for obvious, severe
cellular aggregation as well as fibrous tissue formation encapsulating the implant. *
represents a significant difference from the No Implant, Control Sponge, and Gelfoam®
groups (*p≤0.026, **p<0.0001).
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3.6 Preclinical, Infected, Functional Model of Antimicrobial Efficacy
Although no statistical significances were noted among the groups in both the CFU
count (Fig. 12) and the clearance percentage (Fig. 13), the data gathered from the present
study can provide insight into the efficacy of the experimental thermogel chitosan paste.
Additionally, it can provide valuable evidence about various mechanisms of infection
prevention. S. aureus is known to spread to the surrounding hard and soft tissue much
more so than P. aeruginosa as well as colonizing onto the implant. The systemic
administration of the antibiotics had the lowest average count of S. aureus CFUs for both
the k-wires and surrounding hard tissue. The average count of S. aureus CFUs harvested
from the k-wires ranges between 103 and 104 CFUs, with the systemic antibiotics group
averaging 723 CFUs. The systemic antibiotic administration cleared 75% of k-wires of
S. aureus. Both the thermogel and PEG Paste eradicated all S. aureus microbials in 25%
of k-wires. However, all methods of prophylaxis allowed some proliferation and
migration of S. aureus to the surrounding tissues.
With an average P. aeruginosa CFU count of 10 per k-wire, the thermogel produced
comparable CFU counts to the Systemic Antibiotics group at 7.5 CFUs and the PEG
Paste at 2 CFUs relative to the high CFU counts of the other experimental groups. The
subjects administered antibiotics via the thermogel and PEG Paste delivery systems
effectively prevented the colonization of P. aeruginosa on 75% of implanted k-wires,
while administration of antibiotics systemically cleared infection in 50% of explanted kwires. The subjects treated with the Control Sponge formed an average of 88 CFUs per
k-wire and did not clear infection in any of the implanted pins and was not lower than the
negative control group.
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As for the results gathered from the femoral hard tissue, the thermogel delivery
device most effectively inhibited the growth of P. aeruginosa with the lowest average
CFU count, 72.5 CFUs per samples, and highest clearance ability, 50% of samples.
The PEG paste group did present the highest average CFU count in the surrounding
tissue among all groups, with approximately 1000 CFUs per sample. It is possible the
thermogel group conforms to the wound prior to the thermo-responsive gelation; as
opposed to the more viscous consistency of the PEG paste.
While the subject size of the experiment is limited, cross-referencing applicable
data such as the results of the in vivo antimicrobial study and the in vitro antibiotic
elution study can help lead to conclusions. Based on CFU counts alone, all methods
of prophylaxis proved ineffective in preventing the bacterial adherence, colonization,
and formation of biofilm. The aggressive invasion, colonization, and biofilm
formation of S. aureus is not surprising, as Staphylococcal bacterial species have been
reported as the most commonly isolated microbial organisms from orthopaedic
implants and devices [77], capable of efficient biofilm formation [78], with a rapid
growth in bone tissue [79]. It has also has been noted that glycopeptide antibiotics,
such as vancomycin, do not effectively penetrate tissue, an explanation for the poor
antimicrobial efficacy in the femoral tissue samples surrounding the implant [80].
Many observations can be made from the results of the P. aeruginosa CFU counts.
For example, one could imply the P. aeruginosa organism does not thrive in this
murine orthopaedic model as well as the S. aureus bacterial species did. The
thermogel appears to be the most effective antibiotic delivery system in preventing the
colonization of P. aeruginosa as well as effectively eliminating the presence of the
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bacteria altogether. A cross-reference of the results of the antibiotic elution profile, ZOI
analysis, and the in vivo antimicrobial study supports the previous conclusion.
Intermolecular interactions between the aminoglycoside antibiotic and the polyelectrolyte
complex originating between the polycationic chitosan backbone and the β-GP additive
could enhance the efficacy of drug delivery vehicle. Just as electrostatic forces allow
aminoglycosides to bind to the RNA complexes within a microbial organism, there could
be similar forces attracting the amikacin to the thermogel [60, 81, 82].
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Figure 12: Box and whisker plot of the average number of Colony Forming Units (CFUs)
of the re retrieved from the (A) explanted Kirshner wires and (B) homogenates of
surrounding femoral hard tissue; the mean is represented as a (+) with a box and whisker
analysis, α of 5%
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Figure 13: Infection-clearance ability of prophylactic methods, represented as the
percentage of (A) k-wires and (B) hard tissue samples cleared of infection, meaning the
CFU count is zero.
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Conclusion
The functional and clinical efficacy of the thermogel are evaluated within the
scope of musculoskeletal wounds resultant of high energy trauma at risk of infection.
Findings reveal thermogel is an injectable and degradable biomaterial capable of
point-of-care antibiotic loading, and local, therapeutic antibiotic release. There is
room for improvement in the cytocompatibility of the thermogel, yet a cellular
viability response similar to the cytocompatible Control Sponge group is a positive
sign. In vitro studies reveal the thermogel chitosan paste is more susceptible to
enzymatic degradation than the Control Sponge and Particulate. The antibiotic
elution profiles and activity of the thermogel experimental group demonstrate a more
efficient mechanism of drug release compared to the chitosan Control groups; with an
apparent affinity for amikacin over vancomycin, potentially due to intermolecular
interactions. The thermogel displayed favorable injectability prior to the thermoresponsive gelation; with forces of ejection comparable to the PEG paste benchmark
group. Preclinical studies of functional compatibility and antimicrobial efficacy
demonstrate the thermogel is capable of treating an established bacterial
contamination and eliciting a minimal foreign body reaction. The inflammatory
response provoked by the thermogel is less severe than the PEG Paste and more
severe than the control groups. The animal subjects receiving the implants did not
demonstrate any signs of discomfort or pain caused by the thermogel. The preclinical
study of antimicrobial efficacy indicates thermogel as an effective infection
prevention tool in an infected, complex musculoskeletal wound.
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The formulation of the thermogel should be further researched with hopes of
modifications or additives capable of extending antibiotic elution time and efficacy,
as well as improving the cytotoxic response and in vivo biocompatibility. Potential
modifications to the thermogel may be a lower β-GP content which could improve the
cytocompatibility. Additionally, a higher ratio of neutral chitosan particulate to acidic
chitosan in the formulation could result in both improved compatibility and drug release
characteristics. Improvements could be made to the grinding process of the lyophilized
chitosan sponges in order to achieve more uniform flake size which can be measured.
Also, a more finely ground particulate could help create a more homogenous paste. If the
in vivo compatibility of the paste can be improved, then future work will further evaluate
the thermogel drug delivery system in an expanded preclinical model of complex,
infected extremity trauma that more closely represents a human musculoskeletal wound.
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CHAPTER 4: Discussion
Complex musculoskeletal wound infections, especially those complicated by biofilmforming bacteria, can lengthen the healing process, require additional surgeries,
significantly increasing medical costs, and potentially result in patient morbidity [11, 12,
130, 131]. The complex morphology of the wound potentiates the formation of biofilm,
initiated by the adherence of invading planktonic bacteria; resulting in a bolstered
resistance to antimicrobial agents [15, 16]. Consequently, biofilm-forming bacterial
strains including Staphylococcus aureus and Pseudomonas aeruginosa are among the
most common contaminants of complex musculoskeletal infections [17, 18]. Biofilmforming bacterial infections can be cleared with increased systemic antibiotic levels, as
the minimal inhibitory concentration (MIC) of biofilm-forming bacterial colonies can be
up to 1000 times higher than the planktonic form [14]; however, very high systemic
antibiotic concentrations can cause adverse side effects such as nephrotoxicity and
ototoxicity [19]. The clinical need for local drug delivery devices that effectively prevent
bacterial contamination while demonstrating favorable biocompatibility,
biodegradability, and the capability of antibiotic loading at the time of surgical
intervention motivated research into antibiotic-loaded chitosan in many forms including
films, coatings, hydrogels, and lyophilized sponges [25, 27, 34, 121, 129]. Chitosan
sponges were then modified into a paste form to address device migration and wound
coverage, while maintaining the beneficial degradability, biocompatibility, and drug
elution qualities [1, 36]. The research evaluated if chitosan/PEG blended sponges
fabricated into an injectable form could function as a local antibiotic delivery device.
The previously detailed studies sought to determine if lyophilized chitosan composited
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with β-GP and processed into a paste can locally deliver antibiotics while
demonstrating favorable biocompatibility, degradability, antibiotic elution, and
material properties supporting the functional and clinical efficacy of the device.
The goal of the work reported in the current study is to develop an infectionprevention tool to be used in trauma care, effectively reducing the incidence of
morbidity associated with musculoskeletal wounds resultant of traumatic injuries.
Among other predictions, it was hypothesized the thermogel chitosan paste
formulation would form a biocompatible, bio-resorbable, temperature-responsive
drug delivery polymer exhibiting favorable injectability at room temperature (20ºC)
and subsequent in situ gelation as the environmental temperature rises to bodily levels
(37ºC). Results from the cytocompatibility assessment of the thermogel exhibit
viability responses by fibroblast-like cells not significantly different from the Control
chitosan sponge samples, a positive finding. However, based on cell count alone, the
thermogel samples produced the lowest cell count among all experimental groups;
indicating a potential area of improvement. Additionally, the in vivo study of
biocompatibility indicated the thermogel produced one of the highest inflammation
reactions, second only to the PEG Paste samples. It can be said the overall
biocompatibility of the thermogel needs improvement. In a study of the cytotoxic
viability response of fibroblast cells to chitosan/β-GP hydrogel formulations by
Ahmadi et al. [35], authors found lowering the content of β-GP in the formulation
resulted in improved biocompatibility. Therefore, lowering the content of β-GP could
potentially improve the biocompatibility of the thermogel experimental paste. After 7
days, the thermogel was enzymatically degraded to 40% ± 3% of the original mass.
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The material properties of the thermogel paste were investigated via characterization
of the degradation rate and the reactive force of ejection from both a small bore and large
bore syringe. The rate of degradation of the thermogel was similar to that of the PEG
paste, a formulation that was shown to have favorable degradation characteristics for use
in traumatic musculoskeletal injuries by Berretta et al. [33]. The thermo-responsive
characteristic of the thermogel proved to be very beneficial. The temperature dependent
low viscosity polymer at room temper demonstrated very low injectability forces similar
to the PEG Paste experimental group, proven to be highly injectable in a study by Beretta
et al. [33], and significantly lower than a similar chitosan paste formulation in a report
described by Rhodes et al. [1].
The thermogel was also hypothesized to be capable of point-of-care antibiotic loading
via hydration; and local, therapeutic release for at least 72 hrs. The results of the the in
vitro antibiotic release characteristics of the thermogel chitosan paste support this
hypothesis; demonstrating an initial drug burst followed by a prolonged release of the
dual-loaded antibiotics at therapeutic levels for a minimum of 72 hours in both the
vancomucin and amikacin elution profiles. Initially, both amikacin and vancomycin were
released from the Control Sponge group at higher concentrations than all other
experimental groups. However, as the study progressed the thermogel demonstrated the
most effecient release of amikacin while the PEG Paste proved the more effective carrier
of vancomycin. The antibiotic release profile of the thermogel paste is comparable to the
favorable drug release characteristics studied in a report by Ruel-Gariepy et al. [63] of
temperature-sensitive drug delivery systems consisting of chitosan hydrogels composited
with β-GP.
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While the subject size of the experiment is limited, cross-referencing applicable
data such as the results of the in vivo antimicrobial study and the in vitro antibiotic
elution study can help provide evidence about the antimicrobial efficacy of the
thermogel. Based on CFU counts alone, all methods of prophylaxis proved ineffective
in preventing the bacterial adherence, colonization, and formation of biofilm. The
aggressive invasion, colonization, and biofilm formation of S. aureus is not surprising,
as Staphylococcal bacterial species have been reported as the most commonly isolated
microbial organisms from orthopaedic implants and devices [77], capable of efficient
biofilm formation [78], with a rapid growth in bone tissue [79]. It has also has been
noted that glycopeptide antibiotics, such as vancomycin, do not effectively penetrate
tissue, an explanation for the poor antimicrobial efficacy in the femoral tissue samples
surrounding the implant [80].
Many observations can be made from the results of the P. aeruginosa CFU counts.
For example, one could imply the P. aeruginosa organism does not thrive in the
murine orthopaedic model as well as the S. aureus bacterial species did. The
thermogel appears to be the most effective antibiotic delivery system in preventing the
colonization of P. aeruginosa as well as effectively eliminating the presence of the
bacteria altogether. A cross-reference of the results of the antibiotic elution profile,
ZOI analysis, and the in vivo antimicrobial study supports the previous conclusion.
Intermolecular interactions between the aminoglycoside antibiotic and the
polyelectrolyte complex originating between the polycationic chitosan backbone and
the β-GP additive could enhance the efficacy of drug delivery vehicle. As amikacin is
an aminoglycoside, electrostatic forces of attraction among the polyelectrolyte
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complex of chitosan and β-GP and the positively charged amine groups of amikacin
could be a reason for the favorable pharmacokinetics of the pairing; similar to the
electrostatic forces which bind the antibiotic to the ribosomal structures of bacteria [64,
60, 81, 82].
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CHAPTER 5: Conclusion and Future Recommendations
The functional and clinical efficacy of the thermogel are evaluated within the
scope of musculoskeletal wounds resultant of high energy trauma at risk of infection.
Findings reveal thermogel is an injectable and degradable biomaterial capable of
point-of-care antibiotic loading, and local, therapeutic antibiotic release. While
cytocompatibility is similar to other paste material controls, there was some
inflammation observed in vivo. The preclinical study of antimicrobial efficacy
indicates thermogel as an effective infection prevention tool in an infected, complex
musculoskeletal wound.
The formulation of the thermogel should be further researched with hopes of
modifications or additives capable of extending antibiotic elution time and efficacy,
as well as improving the cytotoxic response and in vivo biocompatibility. Potential
modifications to the thermogel may be a lower β-GP content which could improve the
cytocompatibility. Additionally, a higher ratio of neutral chitosan particulate to
acidic chitosan in the formulation could result in both improved compatibility and
drug release characteristics. Improvements could be made to the grinding process of
the lyophilized chitosan sponges in order to achieve more uniform flake size which
can be measured. Also, a more finely ground particulate could help create a more
homogenous paste. If the in vivo compatibility of the paste can be improved, then
future work will further evaluate the thermogel drug delivery system in an expanded
preclinical model of complex, infected extremity trauma that more closely represents
a human musculoskeletal wound.
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APPENDICES
I.

Supplemental Studies

Chitosan Paste Antibiotic Diffusion
Objective
An agar wound model was created to visually characterize the diffusivity of the
antibiotics from the experimental chitosan drug delivery vehicles.
Materials and Methods
Agar molds were made using 20ml of 1.5% (wt) agar solution cast in petri dishes
and chilled overnight at 3°C. The goal was to create a reproducible pattern in the agar
mold representative of a complex musculoskeletal wound. A circle with a diameter of
8mm was carved out of the center of the agar mold and 8 micro-channels radiating
from the center, each 45° apart, were cut into the mold with a No. 11 scalpel blade
(Fig 4A). Experimental samples (n=3) of the PEG paste (26mg), thermogel paste
(24mg), Control particulate (24mg), and Control sponges (24mg coupons) were
hydrated with 0.2ml of PBS loaded with Rhodamine B (1mg/ml, Sigma-Aldrich, St.
Louis, MO, USA), a fluorescent red dye with a similar molecular weight to amikacin,
among other antibiotics. The hydrated sponge or paste samples were placed in the
center cavity of the agar mold, then gently shaken in an incubator (37°C) for 30
minutes. The diffusion pattern of Rhodamine B was fluoresced at an excitation
wavelength of 553nm and emission of 627nm; imaged at 4X and stitched together into
a montage via a Nikon inverted microscope Eclipse TE300 (Nikon Instruments
Incorporation, Melville, NY, USA) operated by BIOQUANT OSTEO16 imaging
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software (BIOQUANT, Nashville, TN, USA). From the newly created montage, the area
of fluorescence from the Rhodamine B was then calculated with the thresholding tool on
the BIOQUANT OSTEO16 software which counted the number of pixels of a certain
color and converted the pixel count to an area value in mm2 based on calibration with a
pinwheel micrometer calibration slide.

100

Figure 3: Chitosan paste dry components prepared to be dyed with rhodamine B for the
antibiotic diffusion test.

B

A

Figure 4: (A) Agar mold with hydrated control sponge coupon in center cavity and
radiating micro channels; (B) montage of fluoresced Rhodamine B diffusing from drug
delivery device created using BIOQUANT OSTEO16 imaging software.
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Results & Discussion
The Control Sponge samples created an area of fluorescence by the model antibiotic
solution which was significantly larger than all other experimental groups (p<0.02). The
calculated area of diffusion is supported by the in vitro antibiotic release profile. Just as
the Control Sponge samples displayed an initial burst release of the loaded antibiotics in
the antibiotic elution study, the antibiotic diffusion maps helped to qualitatively model
the quick release of antibiotics from the Control Sponge group. The experimental design
should be modified to examine the antibiotic diffusion characteristics over time to help
better understand the mechanisms most essential to improving drug delivery
characteristics in the chitosan paste.
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Figure 5. Montage of rhodamine dyed antibiotic-PBS solution to model antibiotic
diffusion from the experimental samples (n=3); (A) Control Sponge, (B) Control
Particulate, (C) PEG paste, (D) thermogel.
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Figure 6: Calculated area of diffusion of rhodamine dyed antibiotic-PBS solution (n=3),
data is presented as the average area of diffusion ± STD. * represents a significantly
lower diffusion area than the Control Sponge group (*p<0.019, **p<0.001)
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Chitosan Paste Conformation in Agar Wound Model
Objective
The objective of the conformation study was to qualitatively assess and
characterize the quality of thermogel paste conformation to model deep, narrow
wound beds in comparison to other chitosan delivery system variations.
Materials and Methods
Model wound beds with narrow, deep crevices were made from 1.5% (wt) agar,
cast in 50ml centrifuge tubes (Corning, Corning, NY, USA) with a crevice to the
bottom, and chilled overnight at 3°C. Experimental chitosan samples (n=3, 120mg of
thermogel paste, control sponge and particulate, and 133mg of the PEG paste) are
hydrated with 1ml of PBS loaded with Rhodamine B (1mg/ml, Sigma-Aldrich, St.
Louis, MO, USA). The model agar wound beds are then incubated to 37°C, the
hydrated samples placed at the top of the wound (Fig. 7), and gently shaken in an
incubator (37°C) for 30 minutes. The model wound beds are then bisected and
imaged. The quality of conformation to the wound is then visually assessed, and
qualitatively analyzed as a proof of principle (Fig. 8).
Results & Discussion
The level of conformation exhibited by samples from each experimental group can
be visually assessed. The Control Chitosan Sponge and Particulate displayed an
inability to conform to the wound bed and deliver the loaded antibiotics to the far
reaches of the model wound. The Control Sponge displayed a burst release of the
loaded solution as it was lodged in the top of the wound. Both the thermogel and PEG
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Paste experimental formulations displayed an improved coverage of the wound compared
to the control chitosan groups. Among the experimental paste groups, the thermogel
appeared to more effectively distribute the antibiotic solution while conforming to the
wound. Findings from the current study are supported by the injectability results. A
potential benefit of adding β-GP to the chitosan paste formulation is improved handling
properties, due to the low viscosity of the paste at room temperature (20°C). The authors
of a review of thermo-responsive drug delivery systems noted the chitosan-acetic acid-βGP mixtures displayed a liquidlike behavior at low temperatures before undergoing a
gelation process at higher temperatures [124].
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Figure 7: Agar model wound bed with dyed sponge inserted.
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Figure 8: Model agar wound molds to evaluate paste conformity to narrow wound bed;
(A) Control Sponge, (B) Control Paste, (C) PEG Paste, (D) thermogel.
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Bio-adhesive Characterization of Chitosan Drug Delivery Devices
Objective
The bio-adhesive study was a preliminary assessment of the adhesive quality
displayed by the chitosan paste and sponge to musculoskeletal tissue in a model
porcine wound.
Materials and Methods
A longitudinal incision, approximately 7cm in length is made superficially to the
scapular region of recently sacrificed neo-natal pigs gathered from the University of
Memphis Animal Research Center. Thermogel (600mg), PEG paste (667mg), control
Sponges (600mg), and Control Particulate (600mg) samples were hydrated with 5ml
of PBS. All porcine test subjects were incubated to 37°C. The chitosan samples (n=3)
were then placed or injected into the wound. The adhesive quality of the biomaterial
was assessed as the implant migration distance within the wound after a 10ml syringe
fitted with an 18-gauge needle (BD™, Franklin Lakes, New Jersey, USA) injected
10ml of PBS subcutaneously at the head of the wound at a flow rate of 1ml/sec for 10
seconds to model the natural exudate of a musculoskeletal wound. As the PBS was
injected into the wound, the subjects with the implanted biomaterial were fixed at a
45° angle to the ground (Fig. 9).
Results & Discussion
No implant migration was observed among any experimental groups. Therefore,
all chitosan paste samples can be considered bio-adhesive for the desired application
of therapeutic release of antibiotics in musculoskeletal wounds. The mucoadhesive
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properties of chitosan have been established, explained by the strong electrostatic force of
the cationic amine groups lining the backbone of chitosan to the anionic mucins,
glycosylated proteins highly concentrated on mucosal tissue surfaces such as pulmonary,
corneal, intestinal, and gastric mucosal tissues [109]. Also, a portion of the
mucoadhesive force can be attributed to the hydrogen bonding between the chitosan and
the mucosal membranes [110]. Mucoadhesion contributes to chitosan adherence to a
musculoskeletal wound via anionic molecules in the musculoskeletal tissue, such as the
anionic proteoglycans comprising connective tissue [111].
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Figure 9: Experimental setup for adhesion testing; (A) model complex musculoskeletal
wound, (B) PEG paste being injected into the wound, (C) subcutaneous saline injection at
the head of the wound.
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II.

Supplemental Figures

Microscopic Analysis of NIH3T3 Cells

Figure 10: Microscope images (40X) displaying cellular morphology of NIH3T3 cells
after 72 hours of indirect exposure to: (A) Control Sponge, (B) Control Particulate, (C)
thermogel, (D) PEG Paste.
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Histological Slide Examples from Functional Compatibility study

A

B
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C

D
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E

Figure 11A-E: Montage of histology slides made from excised rat limbs from functional
compatibility study, stained with hematoxylin and eosin to emphasize the severity of the
host foreign body response characterized by the aggregation of leukocytes and fibrous
tissue formation, areas of interest are magnified to the right of the original image; (A) No
implant control; (B) Control Sponge; (C) thermogel; (D) PEG paste; (E) Gelfoam®.
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Zone of Inhibition Image Analysis

Figure 12: Image results of zone of inhibition analysis of the eluate samples from the (A)
Control Sponge; (B) Control Particulate; (C) PEG Paste; (D) Paste formulation from study
by Rhodes et al [1]; E. thermogel.
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